nodes	percent_of_prediction	percent_of_DWPC	metapath
L-DOPA—PSIP1—neck—thyroid cancer	0.0262	0.134	CbGeAlD
L-DOPA—SLC7A8—neck—thyroid cancer	0.0173	0.0881	CbGeAlD
L-DOPA—PSIP1—trachea—thyroid cancer	0.0158	0.0804	CbGeAlD
L-DOPA—PSIP1—thyroid gland—thyroid cancer	0.0125	0.0636	CbGeAlD
L-DOPA—Liothyronine—THRB—thyroid cancer	0.0112	0.597	CrCbGaD
L-DOPA—PSIP1—head—thyroid cancer	0.0111	0.0564	CbGeAlD
L-DOPA—SLC7A5—saliva-secreting gland—thyroid cancer	0.0105	0.0532	CbGeAlD
L-DOPA—SLC16A10—neck—thyroid cancer	0.0103	0.0523	CbGeAlD
L-DOPA—SLC7A8—thyroid gland—thyroid cancer	0.00823	0.0419	CbGeAlD
L-DOPA—SLC7A5—trachea—thyroid cancer	0.00806	0.0411	CbGeAlD
L-DOPA—PSIP1—lymph node—thyroid cancer	0.00776	0.0395	CbGeAlD
L-DOPA—SLC7A8—head—thyroid cancer	0.0073	0.0372	CbGeAlD
L-DOPA—DRD3—head—thyroid cancer	0.00648	0.033	CbGeAlD
L-DOPA—SLC7A5—thyroid gland—thyroid cancer	0.00638	0.0325	CbGeAlD
L-DOPA—DDC—head—thyroid cancer	0.00632	0.0322	CbGeAlD
L-DOPA—DRD5—head—thyroid cancer	0.00608	0.0309	CbGeAlD
L-DOPA—SLC7A5—head—thyroid cancer	0.00566	0.0288	CbGeAlD
L-DOPA—SLC7A8—lymph node—thyroid cancer	0.00511	0.026	CbGeAlD
L-DOPA—SLC16A10—thyroid gland—thyroid cancer	0.00488	0.0249	CbGeAlD
L-DOPA—DRD1—head—thyroid cancer	0.00464	0.0236	CbGeAlD
L-DOPA—DDC—lymph node—thyroid cancer	0.00442	0.0225	CbGeAlD
L-DOPA—SLC7A5—lymph node—thyroid cancer	0.00396	0.0202	CbGeAlD
L-DOPA—Mesalazine—PPARG—thyroid cancer	0.00383	0.205	CrCbGaD
L-DOPA—SLC16A10—lymph node—thyroid cancer	0.00303	0.0155	CbGeAlD
L-DOPA—DRD2—head—thyroid cancer	0.00274	0.014	CbGeAlD
L-DOPA—Urinary tract disorder—Sorafenib—thyroid cancer	0.00233	0.00438	CcSEcCtD
L-DOPA—Urethral disorder—Sorafenib—thyroid cancer	0.00232	0.00434	CcSEcCtD
L-DOPA—Insomnia—Vandetanib—thyroid cancer	0.00225	0.00422	CcSEcCtD
L-DOPA—Paraesthesia—Vandetanib—thyroid cancer	0.00224	0.00419	CcSEcCtD
L-DOPA—Blister—Doxorubicin—thyroid cancer	0.00223	0.00419	CcSEcCtD
L-DOPA—Dyspnoea—Vandetanib—thyroid cancer	0.00222	0.00416	CcSEcCtD
L-DOPA—Flushing—Sorafenib—thyroid cancer	0.00219	0.00411	CcSEcCtD
L-DOPA—Dyspepsia—Vandetanib—thyroid cancer	0.00219	0.00411	CcSEcCtD
L-DOPA—Decreased appetite—Vandetanib—thyroid cancer	0.00216	0.00406	CcSEcCtD
L-DOPA—Gastrointestinal disorder—Vandetanib—thyroid cancer	0.00215	0.00403	CcSEcCtD
L-DOPA—Fatigue—Vandetanib—thyroid cancer	0.00215	0.00402	CcSEcCtD
L-DOPA—Constipation—Vandetanib—thyroid cancer	0.00213	0.00399	CcSEcCtD
L-DOPA—Pain—Vandetanib—thyroid cancer	0.00213	0.00399	CcSEcCtD
L-DOPA—Dysphonia—Epirubicin—thyroid cancer	0.00211	0.00396	CcSEcCtD
L-DOPA—Arrhythmia—Sorafenib—thyroid cancer	0.00211	0.00396	CcSEcCtD
L-DOPA—Alopecia—Sorafenib—thyroid cancer	0.00209	0.00392	CcSEcCtD
L-DOPA—Blood disorder—Epirubicin—thyroid cancer	0.00208	0.0039	CcSEcCtD
L-DOPA—Mental disorder—Sorafenib—thyroid cancer	0.00207	0.00388	CcSEcCtD
L-DOPA—Aminosalicylic Acid—PTGS2—thyroid cancer	0.00206	0.11	CrCbGaD
L-DOPA—Gastrointestinal pain—Vandetanib—thyroid cancer	0.00204	0.00382	CcSEcCtD
L-DOPA—Dysgeusia—Sorafenib—thyroid cancer	0.00202	0.00378	CcSEcCtD
L-DOPA—Cardiovascular disorder—Epirubicin—thyroid cancer	0.00198	0.00371	CcSEcCtD
L-DOPA—Muscle spasms—Sorafenib—thyroid cancer	0.00198	0.00371	CcSEcCtD
L-DOPA—Abdominal pain—Vandetanib—thyroid cancer	0.00197	0.00369	CcSEcCtD
L-DOPA—Dysphonia—Doxorubicin—thyroid cancer	0.00196	0.00367	CcSEcCtD
L-DOPA—Blood disorder—Doxorubicin—thyroid cancer	0.00193	0.00361	CcSEcCtD
L-DOPA—Anaemia—Sorafenib—thyroid cancer	0.0019	0.00357	CcSEcCtD
L-DOPA—Angioedema—Sorafenib—thyroid cancer	0.00188	0.00352	CcSEcCtD
L-DOPA—Dyskinesia—Epirubicin—thyroid cancer	0.00185	0.00347	CcSEcCtD
L-DOPA—Syncope—Sorafenib—thyroid cancer	0.00185	0.00346	CcSEcCtD
L-DOPA—Leukopenia—Sorafenib—thyroid cancer	0.00184	0.00345	CcSEcCtD
L-DOPA—Cardiovascular disorder—Doxorubicin—thyroid cancer	0.00183	0.00343	CcSEcCtD
L-DOPA—Loss of consciousness—Sorafenib—thyroid cancer	0.00181	0.00339	CcSEcCtD
L-DOPA—Cough—Sorafenib—thyroid cancer	0.0018	0.00337	CcSEcCtD
L-DOPA—Asthenia—Vandetanib—thyroid cancer	0.00179	0.00335	CcSEcCtD
L-DOPA—Gait disturbance—Epirubicin—thyroid cancer	0.00178	0.00334	CcSEcCtD
L-DOPA—Hypertension—Sorafenib—thyroid cancer	0.00178	0.00333	CcSEcCtD
L-DOPA—Pruritus—Vandetanib—thyroid cancer	0.00176	0.0033	CcSEcCtD
L-DOPA—Musculoskeletal pain—Epirubicin—thyroid cancer	0.00176	0.0033	CcSEcCtD
L-DOPA—Hiccups—Epirubicin—thyroid cancer	0.00174	0.00326	CcSEcCtD
L-DOPA—Dry mouth—Sorafenib—thyroid cancer	0.00171	0.00321	CcSEcCtD
L-DOPA—Dyskinesia—Doxorubicin—thyroid cancer	0.00171	0.00321	CcSEcCtD
L-DOPA—Diarrhoea—Vandetanib—thyroid cancer	0.0017	0.00319	CcSEcCtD
L-DOPA—Salivary hypersecretion—Epirubicin—thyroid cancer	0.00169	0.00317	CcSEcCtD
L-DOPA—Shock—Sorafenib—thyroid cancer	0.00165	0.0031	CcSEcCtD
L-DOPA—Gait disturbance—Doxorubicin—thyroid cancer	0.00165	0.00309	CcSEcCtD
L-DOPA—CYP2D6—head—thyroid cancer	0.00165	0.00839	CbGeAlD
L-DOPA—Dizziness—Vandetanib—thyroid cancer	0.00165	0.00309	CcSEcCtD
L-DOPA—Thrombocytopenia—Sorafenib—thyroid cancer	0.00164	0.00308	CcSEcCtD
L-DOPA—Blood urea increased—Epirubicin—thyroid cancer	0.00164	0.00308	CcSEcCtD
L-DOPA—Musculoskeletal pain—Doxorubicin—thyroid cancer	0.00163	0.00305	CcSEcCtD
L-DOPA—Mesalazine—PTGS2—thyroid cancer	0.00162	0.0867	CrCbGaD
L-DOPA—Hiccups—Doxorubicin—thyroid cancer	0.00161	0.00302	CcSEcCtD
L-DOPA—Anorexia—Sorafenib—thyroid cancer	0.0016	0.003	CcSEcCtD
L-DOPA—Vomiting—Vandetanib—thyroid cancer	0.00158	0.00297	CcSEcCtD
L-DOPA—Rash—Vandetanib—thyroid cancer	0.00157	0.00294	CcSEcCtD
L-DOPA—Dermatitis—Vandetanib—thyroid cancer	0.00157	0.00294	CcSEcCtD
L-DOPA—Salivary hypersecretion—Doxorubicin—thyroid cancer	0.00156	0.00293	CcSEcCtD
L-DOPA—Headache—Vandetanib—thyroid cancer	0.00156	0.00292	CcSEcCtD
L-DOPA—Blood urea increased—Doxorubicin—thyroid cancer	0.00152	0.00285	CcSEcCtD
L-DOPA—Dyspnoea—Sorafenib—thyroid cancer	0.0015	0.00281	CcSEcCtD
L-DOPA—Nausea—Vandetanib—thyroid cancer	0.00148	0.00277	CcSEcCtD
L-DOPA—Dyspepsia—Sorafenib—thyroid cancer	0.00148	0.00277	CcSEcCtD
L-DOPA—Phlebitis—Epirubicin—thyroid cancer	0.00147	0.00275	CcSEcCtD
L-DOPA—Decreased appetite—Sorafenib—thyroid cancer	0.00146	0.00274	CcSEcCtD
L-DOPA—Gastrointestinal disorder—Sorafenib—thyroid cancer	0.00145	0.00272	CcSEcCtD
L-DOPA—Fatigue—Sorafenib—thyroid cancer	0.00145	0.00271	CcSEcCtD
L-DOPA—Pain—Sorafenib—thyroid cancer	0.00144	0.00269	CcSEcCtD
L-DOPA—Constipation—Sorafenib—thyroid cancer	0.00144	0.00269	CcSEcCtD
L-DOPA—Vascular purpura—Epirubicin—thyroid cancer	0.00141	0.00265	CcSEcCtD
L-DOPA—Gastrointestinal pain—Sorafenib—thyroid cancer	0.00137	0.00257	CcSEcCtD
L-DOPA—Phlebitis—Doxorubicin—thyroid cancer	0.00136	0.00254	CcSEcCtD
L-DOPA—Hot flush—Epirubicin—thyroid cancer	0.00135	0.00253	CcSEcCtD
L-DOPA—Menopausal symptoms—Epirubicin—thyroid cancer	0.00134	0.00251	CcSEcCtD
L-DOPA—Urticaria—Sorafenib—thyroid cancer	0.00133	0.0025	CcSEcCtD
L-DOPA—Abdominal pain—Sorafenib—thyroid cancer	0.00133	0.00249	CcSEcCtD
L-DOPA—Dermatitis bullous—Epirubicin—thyroid cancer	0.00132	0.00248	CcSEcCtD
L-DOPA—Purpura—Epirubicin—thyroid cancer	0.00131	0.00246	CcSEcCtD
L-DOPA—Vascular purpura—Doxorubicin—thyroid cancer	0.00131	0.00245	CcSEcCtD
L-DOPA—Gastrointestinal haemorrhage—Epirubicin—thyroid cancer	0.00126	0.00237	CcSEcCtD
L-DOPA—Pain in extremity—Epirubicin—thyroid cancer	0.00126	0.00237	CcSEcCtD
L-DOPA—Diplopia—Epirubicin—thyroid cancer	0.00126	0.00237	CcSEcCtD
L-DOPA—Hot flush—Doxorubicin—thyroid cancer	0.00125	0.00234	CcSEcCtD
L-DOPA—Menopausal symptoms—Doxorubicin—thyroid cancer	0.00124	0.00232	CcSEcCtD
L-DOPA—Hypersensitivity—Sorafenib—thyroid cancer	0.00124	0.00232	CcSEcCtD
L-DOPA—Dermatitis bullous—Doxorubicin—thyroid cancer	0.00122	0.00229	CcSEcCtD
L-DOPA—Purpura—Doxorubicin—thyroid cancer	0.00121	0.00227	CcSEcCtD
L-DOPA—Asthenia—Sorafenib—thyroid cancer	0.00121	0.00226	CcSEcCtD
L-DOPA—Pruritus—Sorafenib—thyroid cancer	0.00119	0.00223	CcSEcCtD
L-DOPA—Ataxia—Epirubicin—thyroid cancer	0.00119	0.00223	CcSEcCtD
L-DOPA—Blood creatinine increased—Epirubicin—thyroid cancer	0.00118	0.00222	CcSEcCtD
L-DOPA—Pain in extremity—Doxorubicin—thyroid cancer	0.00117	0.00219	CcSEcCtD
L-DOPA—Gastrointestinal haemorrhage—Doxorubicin—thyroid cancer	0.00117	0.00219	CcSEcCtD
L-DOPA—Diplopia—Doxorubicin—thyroid cancer	0.00117	0.00219	CcSEcCtD
L-DOPA—Orthostatic hypotension—Epirubicin—thyroid cancer	0.00115	0.00216	CcSEcCtD
L-DOPA—Diarrhoea—Sorafenib—thyroid cancer	0.00115	0.00215	CcSEcCtD
L-DOPA—Nasopharyngitis—Epirubicin—thyroid cancer	0.00113	0.00212	CcSEcCtD
L-DOPA—Gastritis—Epirubicin—thyroid cancer	0.00112	0.00209	CcSEcCtD
L-DOPA—Dizziness—Sorafenib—thyroid cancer	0.00111	0.00208	CcSEcCtD
L-DOPA—Ataxia—Doxorubicin—thyroid cancer	0.0011	0.00206	CcSEcCtD
L-DOPA—Blood creatinine increased—Doxorubicin—thyroid cancer	0.00109	0.00205	CcSEcCtD
L-DOPA—Dysphagia—Epirubicin—thyroid cancer	0.00109	0.00205	CcSEcCtD
L-DOPA—Vomiting—Sorafenib—thyroid cancer	0.00107	0.002	CcSEcCtD
L-DOPA—Orthostatic hypotension—Doxorubicin—thyroid cancer	0.00107	0.002	CcSEcCtD
L-DOPA—Angina pectoris—Epirubicin—thyroid cancer	0.00106	0.00199	CcSEcCtD
L-DOPA—Rash—Sorafenib—thyroid cancer	0.00106	0.00198	CcSEcCtD
L-DOPA—Dermatitis—Sorafenib—thyroid cancer	0.00106	0.00198	CcSEcCtD
L-DOPA—Headache—Sorafenib—thyroid cancer	0.00105	0.00197	CcSEcCtD
L-DOPA—Nasopharyngitis—Doxorubicin—thyroid cancer	0.00104	0.00196	CcSEcCtD
L-DOPA—Gastritis—Doxorubicin—thyroid cancer	0.00103	0.00194	CcSEcCtD
L-DOPA—Upper respiratory tract infection—Epirubicin—thyroid cancer	0.00101	0.0019	CcSEcCtD
L-DOPA—Dysphagia—Doxorubicin—thyroid cancer	0.00101	0.00189	CcSEcCtD
L-DOPA—Pollakiuria—Epirubicin—thyroid cancer	0.00101	0.00189	CcSEcCtD
L-DOPA—Nausea—Sorafenib—thyroid cancer	0.000998	0.00187	CcSEcCtD
L-DOPA—Weight increased—Epirubicin—thyroid cancer	0.000993	0.00186	CcSEcCtD
L-DOPA—Weight decreased—Epirubicin—thyroid cancer	0.000988	0.00185	CcSEcCtD
L-DOPA—Angina pectoris—Doxorubicin—thyroid cancer	0.000984	0.00184	CcSEcCtD
L-DOPA—Neuropathy peripheral—Epirubicin—thyroid cancer	0.000954	0.00179	CcSEcCtD
L-DOPA—Urinary tract infection—Epirubicin—thyroid cancer	0.000946	0.00177	CcSEcCtD
L-DOPA—Upper respiratory tract infection—Doxorubicin—thyroid cancer	0.000939	0.00176	CcSEcCtD
L-DOPA—Pollakiuria—Doxorubicin—thyroid cancer	0.000933	0.00175	CcSEcCtD
L-DOPA—Weight increased—Doxorubicin—thyroid cancer	0.000919	0.00172	CcSEcCtD
L-DOPA—Weight decreased—Doxorubicin—thyroid cancer	0.000914	0.00171	CcSEcCtD
L-DOPA—Agranulocytosis—Epirubicin—thyroid cancer	0.000908	0.0017	CcSEcCtD
L-DOPA—Neuropathy peripheral—Doxorubicin—thyroid cancer	0.000883	0.00165	CcSEcCtD
L-DOPA—Haemoglobin—Epirubicin—thyroid cancer	0.000878	0.00165	CcSEcCtD
L-DOPA—Rhinitis—Epirubicin—thyroid cancer	0.000876	0.00164	CcSEcCtD
L-DOPA—Urinary tract infection—Doxorubicin—thyroid cancer	0.000875	0.00164	CcSEcCtD
L-DOPA—Haemorrhage—Epirubicin—thyroid cancer	0.000874	0.00164	CcSEcCtD
L-DOPA—Hypoaesthesia—Epirubicin—thyroid cancer	0.000869	0.00163	CcSEcCtD
L-DOPA—Urinary tract disorder—Epirubicin—thyroid cancer	0.000863	0.00162	CcSEcCtD
L-DOPA—Urethral disorder—Epirubicin—thyroid cancer	0.000856	0.00161	CcSEcCtD
L-DOPA—Agranulocytosis—Doxorubicin—thyroid cancer	0.00084	0.00158	CcSEcCtD
L-DOPA—Haemoglobin—Doxorubicin—thyroid cancer	0.000813	0.00152	CcSEcCtD
L-DOPA—Flushing—Epirubicin—thyroid cancer	0.000811	0.00152	CcSEcCtD
L-DOPA—Rhinitis—Doxorubicin—thyroid cancer	0.00081	0.00152	CcSEcCtD
L-DOPA—Haemorrhage—Doxorubicin—thyroid cancer	0.000808	0.00152	CcSEcCtD
L-DOPA—Hypoaesthesia—Doxorubicin—thyroid cancer	0.000804	0.00151	CcSEcCtD
L-DOPA—Urinary tract disorder—Doxorubicin—thyroid cancer	0.000798	0.0015	CcSEcCtD
L-DOPA—Urethral disorder—Doxorubicin—thyroid cancer	0.000792	0.00149	CcSEcCtD
L-DOPA—Arrhythmia—Epirubicin—thyroid cancer	0.000781	0.00146	CcSEcCtD
L-DOPA—Alopecia—Epirubicin—thyroid cancer	0.000772	0.00145	CcSEcCtD
L-DOPA—Mental disorder—Epirubicin—thyroid cancer	0.000765	0.00143	CcSEcCtD
L-DOPA—Flushing—Doxorubicin—thyroid cancer	0.00075	0.00141	CcSEcCtD
L-DOPA—Flatulence—Epirubicin—thyroid cancer	0.000749	0.0014	CcSEcCtD
L-DOPA—Tension—Epirubicin—thyroid cancer	0.000746	0.0014	CcSEcCtD
L-DOPA—Dysgeusia—Epirubicin—thyroid cancer	0.000745	0.0014	CcSEcCtD
L-DOPA—Nervousness—Epirubicin—thyroid cancer	0.000739	0.00138	CcSEcCtD
L-DOPA—Back pain—Epirubicin—thyroid cancer	0.000736	0.00138	CcSEcCtD
L-DOPA—Muscle spasms—Epirubicin—thyroid cancer	0.000731	0.00137	CcSEcCtD
L-DOPA—Arrhythmia—Doxorubicin—thyroid cancer	0.000722	0.00135	CcSEcCtD
L-DOPA—Vision blurred—Epirubicin—thyroid cancer	0.000717	0.00134	CcSEcCtD
L-DOPA—Alopecia—Doxorubicin—thyroid cancer	0.000714	0.00134	CcSEcCtD
L-DOPA—Mental disorder—Doxorubicin—thyroid cancer	0.000708	0.00133	CcSEcCtD
L-DOPA—Ill-defined disorder—Epirubicin—thyroid cancer	0.000706	0.00132	CcSEcCtD
L-DOPA—Anaemia—Epirubicin—thyroid cancer	0.000703	0.00132	CcSEcCtD
L-DOPA—Agitation—Epirubicin—thyroid cancer	0.000699	0.00131	CcSEcCtD
L-DOPA—Flatulence—Doxorubicin—thyroid cancer	0.000693	0.0013	CcSEcCtD
L-DOPA—Tension—Doxorubicin—thyroid cancer	0.000691	0.00129	CcSEcCtD
L-DOPA—Dysgeusia—Doxorubicin—thyroid cancer	0.000689	0.00129	CcSEcCtD
L-DOPA—Malaise—Epirubicin—thyroid cancer	0.000686	0.00129	CcSEcCtD
L-DOPA—Nervousness—Doxorubicin—thyroid cancer	0.000684	0.00128	CcSEcCtD
L-DOPA—Syncope—Epirubicin—thyroid cancer	0.000682	0.00128	CcSEcCtD
L-DOPA—Leukopenia—Epirubicin—thyroid cancer	0.000681	0.00128	CcSEcCtD
L-DOPA—Back pain—Doxorubicin—thyroid cancer	0.000681	0.00128	CcSEcCtD
L-DOPA—Muscle spasms—Doxorubicin—thyroid cancer	0.000677	0.00127	CcSEcCtD
L-DOPA—Palpitations—Epirubicin—thyroid cancer	0.000672	0.00126	CcSEcCtD
L-DOPA—Loss of consciousness—Epirubicin—thyroid cancer	0.000668	0.00125	CcSEcCtD
L-DOPA—Cough—Epirubicin—thyroid cancer	0.000664	0.00124	CcSEcCtD
L-DOPA—Vision blurred—Doxorubicin—thyroid cancer	0.000663	0.00124	CcSEcCtD
L-DOPA—Convulsion—Epirubicin—thyroid cancer	0.000659	0.00124	CcSEcCtD
L-DOPA—Hypertension—Epirubicin—thyroid cancer	0.000657	0.00123	CcSEcCtD
L-DOPA—Ill-defined disorder—Doxorubicin—thyroid cancer	0.000653	0.00122	CcSEcCtD
L-DOPA—Anaemia—Doxorubicin—thyroid cancer	0.00065	0.00122	CcSEcCtD
L-DOPA—Chest pain—Epirubicin—thyroid cancer	0.000648	0.00121	CcSEcCtD
L-DOPA—Agitation—Doxorubicin—thyroid cancer	0.000647	0.00121	CcSEcCtD
L-DOPA—Anxiety—Epirubicin—thyroid cancer	0.000645	0.00121	CcSEcCtD
L-DOPA—Discomfort—Epirubicin—thyroid cancer	0.00064	0.0012	CcSEcCtD
L-DOPA—Malaise—Doxorubicin—thyroid cancer	0.000635	0.00119	CcSEcCtD
L-DOPA—Dry mouth—Epirubicin—thyroid cancer	0.000633	0.00119	CcSEcCtD
L-DOPA—Syncope—Doxorubicin—thyroid cancer	0.000631	0.00118	CcSEcCtD
L-DOPA—Leukopenia—Doxorubicin—thyroid cancer	0.00063	0.00118	CcSEcCtD
L-DOPA—Confusional state—Epirubicin—thyroid cancer	0.000626	0.00117	CcSEcCtD
L-DOPA—Palpitations—Doxorubicin—thyroid cancer	0.000622	0.00117	CcSEcCtD
L-DOPA—Oedema—Epirubicin—thyroid cancer	0.000621	0.00116	CcSEcCtD
L-DOPA—Loss of consciousness—Doxorubicin—thyroid cancer	0.000619	0.00116	CcSEcCtD
L-DOPA—Cough—Doxorubicin—thyroid cancer	0.000614	0.00115	CcSEcCtD
L-DOPA—Shock—Epirubicin—thyroid cancer	0.000611	0.00114	CcSEcCtD
L-DOPA—Convulsion—Doxorubicin—thyroid cancer	0.00061	0.00114	CcSEcCtD
L-DOPA—Thrombocytopenia—Epirubicin—thyroid cancer	0.000608	0.00114	CcSEcCtD
L-DOPA—Hypertension—Doxorubicin—thyroid cancer	0.000608	0.00114	CcSEcCtD
L-DOPA—Hyperhidrosis—Epirubicin—thyroid cancer	0.0006	0.00112	CcSEcCtD
L-DOPA—Chest pain—Doxorubicin—thyroid cancer	0.000599	0.00112	CcSEcCtD
L-DOPA—Anxiety—Doxorubicin—thyroid cancer	0.000597	0.00112	CcSEcCtD
L-DOPA—Discomfort—Doxorubicin—thyroid cancer	0.000592	0.00111	CcSEcCtD
L-DOPA—Anorexia—Epirubicin—thyroid cancer	0.000592	0.00111	CcSEcCtD
L-DOPA—Dry mouth—Doxorubicin—thyroid cancer	0.000586	0.0011	CcSEcCtD
L-DOPA—Hypotension—Epirubicin—thyroid cancer	0.00058	0.00109	CcSEcCtD
L-DOPA—Confusional state—Doxorubicin—thyroid cancer	0.000579	0.00109	CcSEcCtD
L-DOPA—Oedema—Doxorubicin—thyroid cancer	0.000574	0.00108	CcSEcCtD
L-DOPA—Shock—Doxorubicin—thyroid cancer	0.000565	0.00106	CcSEcCtD
L-DOPA—Thrombocytopenia—Doxorubicin—thyroid cancer	0.000562	0.00105	CcSEcCtD
L-DOPA—Insomnia—Epirubicin—thyroid cancer	0.000561	0.00105	CcSEcCtD
L-DOPA—Paraesthesia—Epirubicin—thyroid cancer	0.000557	0.00104	CcSEcCtD
L-DOPA—Hyperhidrosis—Doxorubicin—thyroid cancer	0.000555	0.00104	CcSEcCtD
L-DOPA—Dyspnoea—Epirubicin—thyroid cancer	0.000553	0.00104	CcSEcCtD
L-DOPA—Somnolence—Epirubicin—thyroid cancer	0.000552	0.00103	CcSEcCtD
L-DOPA—Anorexia—Doxorubicin—thyroid cancer	0.000547	0.00103	CcSEcCtD
L-DOPA—Dyspepsia—Epirubicin—thyroid cancer	0.000546	0.00102	CcSEcCtD
L-DOPA—Decreased appetite—Epirubicin—thyroid cancer	0.00054	0.00101	CcSEcCtD
L-DOPA—Hypotension—Doxorubicin—thyroid cancer	0.000537	0.00101	CcSEcCtD
L-DOPA—Gastrointestinal disorder—Epirubicin—thyroid cancer	0.000536	0.001	CcSEcCtD
L-DOPA—Fatigue—Epirubicin—thyroid cancer	0.000535	0.001	CcSEcCtD
L-DOPA—Pain—Epirubicin—thyroid cancer	0.000531	0.000995	CcSEcCtD
L-DOPA—Constipation—Epirubicin—thyroid cancer	0.000531	0.000995	CcSEcCtD
L-DOPA—Insomnia—Doxorubicin—thyroid cancer	0.000519	0.000974	CcSEcCtD
L-DOPA—Paraesthesia—Doxorubicin—thyroid cancer	0.000516	0.000967	CcSEcCtD
L-DOPA—Dyspnoea—Doxorubicin—thyroid cancer	0.000512	0.00096	CcSEcCtD
L-DOPA—Feeling abnormal—Epirubicin—thyroid cancer	0.000512	0.000959	CcSEcCtD
L-DOPA—Somnolence—Doxorubicin—thyroid cancer	0.000511	0.000957	CcSEcCtD
L-DOPA—Gastrointestinal pain—Epirubicin—thyroid cancer	0.000508	0.000951	CcSEcCtD
L-DOPA—Dyspepsia—Doxorubicin—thyroid cancer	0.000506	0.000948	CcSEcCtD
L-DOPA—Decreased appetite—Doxorubicin—thyroid cancer	0.000499	0.000936	CcSEcCtD
L-DOPA—Gastrointestinal disorder—Doxorubicin—thyroid cancer	0.000496	0.000929	CcSEcCtD
L-DOPA—Fatigue—Doxorubicin—thyroid cancer	0.000495	0.000928	CcSEcCtD
L-DOPA—Urticaria—Epirubicin—thyroid cancer	0.000493	0.000924	CcSEcCtD
L-DOPA—Constipation—Doxorubicin—thyroid cancer	0.000491	0.000921	CcSEcCtD
L-DOPA—Pain—Doxorubicin—thyroid cancer	0.000491	0.000921	CcSEcCtD
L-DOPA—Abdominal pain—Epirubicin—thyroid cancer	0.000491	0.00092	CcSEcCtD
L-DOPA—Feeling abnormal—Doxorubicin—thyroid cancer	0.000473	0.000887	CcSEcCtD
L-DOPA—Gastrointestinal pain—Doxorubicin—thyroid cancer	0.00047	0.00088	CcSEcCtD
L-DOPA—DRD2—Class A/1 (Rhodopsin-like receptors)—TSHR—thyroid cancer	0.000459	0.00183	CbGpPWpGaD
L-DOPA—Hypersensitivity—Epirubicin—thyroid cancer	0.000457	0.000857	CcSEcCtD
L-DOPA—DRD3—GPCR ligand binding—TSHR—thyroid cancer	0.000457	0.00182	CbGpPWpGaD
L-DOPA—Urticaria—Doxorubicin—thyroid cancer	0.000456	0.000855	CcSEcCtD
L-DOPA—DRD5—Signaling Pathways—CALCB—thyroid cancer	0.000456	0.00181	CbGpPWpGaD
L-DOPA—Abdominal pain—Doxorubicin—thyroid cancer	0.000454	0.000851	CcSEcCtD
L-DOPA—DDC—Circadian rythm related genes—PTEN—thyroid cancer	0.000452	0.0018	CbGpPWpGaD
L-DOPA—DRD2—G alpha (i) signalling events—SST—thyroid cancer	0.000449	0.00179	CbGpPWpGaD
L-DOPA—Asthenia—Epirubicin—thyroid cancer	0.000445	0.000835	CcSEcCtD
L-DOPA—PSIP1—Disease—HIF1A—thyroid cancer	0.00044	0.00175	CbGpPWpGaD
L-DOPA—Pruritus—Epirubicin—thyroid cancer	0.000439	0.000823	CcSEcCtD
L-DOPA—DRD4—GPCR ligand binding—PTCH1—thyroid cancer	0.000437	0.00174	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—TRIM33—thyroid cancer	0.000432	0.00172	CbGpPWpGaD
L-DOPA—DRD2—GPCR downstream signaling—CALCB—thyroid cancer	0.000427	0.0017	CbGpPWpGaD
L-DOPA—Diarrhoea—Epirubicin—thyroid cancer	0.000425	0.000796	CcSEcCtD
L-DOPA—Hypersensitivity—Doxorubicin—thyroid cancer	0.000423	0.000793	CcSEcCtD
L-DOPA—Asthenia—Doxorubicin—thyroid cancer	0.000412	0.000772	CcSEcCtD
L-DOPA—Dizziness—Epirubicin—thyroid cancer	0.00041	0.000769	CcSEcCtD
L-DOPA—Pruritus—Doxorubicin—thyroid cancer	0.000406	0.000762	CcSEcCtD
L-DOPA—SLC16A10—Transmembrane transport of small molecules—RXRA—thyroid cancer	0.000401	0.00159	CbGpPWpGaD
L-DOPA—DRD4—GPCR ligand binding—SST—thyroid cancer	0.0004	0.00159	CbGpPWpGaD
L-DOPA—Vomiting—Epirubicin—thyroid cancer	0.000395	0.00074	CcSEcCtD
L-DOPA—DRD5—GPCR downstream signaling—TSHR—thyroid cancer	0.000394	0.00157	CbGpPWpGaD
L-DOPA—DRD1—GPCR ligand binding—PTCH1—thyroid cancer	0.000394	0.00157	CbGpPWpGaD
L-DOPA—Diarrhoea—Doxorubicin—thyroid cancer	0.000393	0.000737	CcSEcCtD
L-DOPA—Rash—Epirubicin—thyroid cancer	0.000391	0.000734	CcSEcCtD
L-DOPA—Dermatitis—Epirubicin—thyroid cancer	0.000391	0.000733	CcSEcCtD
L-DOPA—Headache—Epirubicin—thyroid cancer	0.000389	0.000729	CcSEcCtD
L-DOPA—DRD3—GPCR ligand binding—PTCH1—thyroid cancer	0.000388	0.00154	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—CALCB—thyroid cancer	0.000387	0.00154	CbGpPWpGaD
L-DOPA—DRD4—GPCR ligand binding—CALCA—thyroid cancer	0.000385	0.00153	CbGpPWpGaD
L-DOPA—DRD4—Circadian rythm related genes—PPARG—thyroid cancer	0.000382	0.00152	CbGpPWpGaD
L-DOPA—Dizziness—Doxorubicin—thyroid cancer	0.00038	0.000712	CcSEcCtD
L-DOPA—SLC15A1—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	0.000371	0.00147	CbGpPWpGaD
L-DOPA—Nausea—Epirubicin—thyroid cancer	0.000369	0.000691	CcSEcCtD
L-DOPA—Vomiting—Doxorubicin—thyroid cancer	0.000365	0.000684	CcSEcCtD
L-DOPA—PSIP1—Disease—BRAF—thyroid cancer	0.000365	0.00145	CbGpPWpGaD
L-DOPA—Rash—Doxorubicin—thyroid cancer	0.000362	0.000679	CcSEcCtD
L-DOPA—Dermatitis—Doxorubicin—thyroid cancer	0.000362	0.000678	CcSEcCtD
L-DOPA—DRD1—GPCR ligand binding—SST—thyroid cancer	0.00036	0.00143	CbGpPWpGaD
L-DOPA—Headache—Doxorubicin—thyroid cancer	0.00036	0.000674	CcSEcCtD
L-DOPA—DRD5—Signaling by GPCR—TSHR—thyroid cancer	0.000358	0.00142	CbGpPWpGaD
L-DOPA—DRD2—Class A/1 (Rhodopsin-like receptors)—SST—thyroid cancer	0.000357	0.00142	CbGpPWpGaD
L-DOPA—DRD3—GPCR ligand binding—SST—thyroid cancer	0.000355	0.00141	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—PRKAR1A—thyroid cancer	0.000352	0.0014	CbGpPWpGaD
L-DOPA—DRD2—GPCR ligand binding—TSHR—thyroid cancer	0.000349	0.00139	CbGpPWpGaD
L-DOPA—DRD1—GPCR ligand binding—CALCA—thyroid cancer	0.000347	0.00138	CbGpPWpGaD
L-DOPA—DRD1—Circadian rythm related genes—PPARG—thyroid cancer	0.000344	0.00137	CbGpPWpGaD
L-DOPA—DRD3—GPCR ligand binding—CALCA—thyroid cancer	0.000342	0.00136	CbGpPWpGaD
L-DOPA—Nausea—Doxorubicin—thyroid cancer	0.000341	0.000639	CcSEcCtD
L-DOPA—DRD3—Circadian rythm related genes—PPARG—thyroid cancer	0.000339	0.00135	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—CALCB—thyroid cancer	0.000337	0.00134	CbGpPWpGaD
L-DOPA—DDC—Metabolism—TPR—thyroid cancer	0.000321	0.00128	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—TRIM33—thyroid cancer	0.000319	0.00127	CbGpPWpGaD
L-DOPA—DDC—Metabolism—PRKAR1A—thyroid cancer	0.000316	0.00126	CbGpPWpGaD
L-DOPA—SLC15A1—Transmembrane transport of small molecules—RXRA—thyroid cancer	0.000312	0.00124	CbGpPWpGaD
L-DOPA—SLC7A8—Hemostasis—NRAS—thyroid cancer	0.000309	0.00123	CbGpPWpGaD
L-DOPA—DDC—Circadian rythm related genes—TP53—thyroid cancer	0.000309	0.00123	CbGpPWpGaD
L-DOPA—DRD5—GPCR downstream signaling—SST—thyroid cancer	0.000306	0.00122	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—PTCH1—thyroid cancer	0.000304	0.00121	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—CALCB—thyroid cancer	0.000303	0.00121	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—CALCB—thyroid cancer	0.000299	0.00119	CbGpPWpGaD
L-DOPA—DRD2—GPCR ligand binding—PTCH1—thyroid cancer	0.000297	0.00118	CbGpPWpGaD
L-DOPA—DRD5—GPCR downstream signaling—CALCA—thyroid cancer	0.000295	0.00117	CbGpPWpGaD
L-DOPA—PSIP1—Disease—PTGS2—thyroid cancer	0.000294	0.00117	CbGpPWpGaD
L-DOPA—DRD4—GPCR downstream signaling—TSHR—thyroid cancer	0.000291	0.00116	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—TCF7L1—thyroid cancer	0.000289	0.00115	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—TRIM33—thyroid cancer	0.000287	0.00114	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—TRIM33—thyroid cancer	0.000284	0.00113	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—SST—thyroid cancer	0.000278	0.00111	CbGpPWpGaD
L-DOPA—CYP2D6—Biological oxidations—RXRA—thyroid cancer	0.000272	0.00108	CbGpPWpGaD
L-DOPA—DRD2—GPCR ligand binding—SST—thyroid cancer	0.000272	0.00108	CbGpPWpGaD
L-DOPA—SLC7A5—Hemostasis—NRAS—thyroid cancer	0.000269	0.00107	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—CALCA—thyroid cancer	0.000268	0.00106	CbGpPWpGaD
L-DOPA—SLC7A8—Hemostasis—KRAS—thyroid cancer	0.000266	0.00106	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—TSHR—thyroid cancer	0.000264	0.00105	CbGpPWpGaD
L-DOPA—DRD4—Circadian rythm related genes—PTEN—thyroid cancer	0.000262	0.00104	CbGpPWpGaD
L-DOPA—DRD2—GPCR ligand binding—CALCA—thyroid cancer	0.000262	0.00104	CbGpPWpGaD
L-DOPA—DRD1—GPCR downstream signaling—TSHR—thyroid cancer	0.000262	0.00104	CbGpPWpGaD
L-DOPA—DRD2—Circadian rythm related genes—PPARG—thyroid cancer	0.00026	0.00103	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—PRKAR1A—thyroid cancer	0.00026	0.00103	CbGpPWpGaD
L-DOPA—DRD3—GPCR downstream signaling—TSHR—thyroid cancer	0.000258	0.00103	CbGpPWpGaD
L-DOPA—PSIP1—Disease—PTEN—thyroid cancer	0.000257	0.00102	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—CDK1—thyroid cancer	0.000242	0.000963	CbGpPWpGaD
L-DOPA—DDC—Metabolism—SLC5A5—thyroid cancer	0.000241	0.000957	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—TSHR—thyroid cancer	0.000238	0.000945	CbGpPWpGaD
L-DOPA—SLC7A8—Hemostasis—TP53—thyroid cancer	0.000236	0.000939	CbGpPWpGaD
L-DOPA—DRD1—Circadian rythm related genes—PTEN—thyroid cancer	0.000236	0.000939	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—TSHR—thyroid cancer	0.000234	0.000932	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—PRKAR1A—thyroid cancer	0.000234	0.000929	CbGpPWpGaD
L-DOPA—DRD3—Circadian rythm related genes—PTEN—thyroid cancer	0.000233	0.000926	CbGpPWpGaD
L-DOPA—SLC7A5—Hemostasis—KRAS—thyroid cancer	0.000232	0.000922	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—PRKAR1A—thyroid cancer	0.000231	0.000917	CbGpPWpGaD
L-DOPA—PSIP1—Disease—NRAS—thyroid cancer	0.000229	0.000911	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—CALCB—thyroid cancer	0.000229	0.00091	CbGpPWpGaD
L-DOPA—DRD4—GPCR downstream signaling—SST—thyroid cancer	0.000226	0.000899	CbGpPWpGaD
L-DOPA—SLC7A8—Hemostasis—HRAS—thyroid cancer	0.000226	0.000898	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—PTCH1—thyroid cancer	0.000224	0.000892	CbGpPWpGaD
L-DOPA—DRD4—GPCR downstream signaling—CALCA—thyroid cancer	0.000218	0.000865	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—TRIM33—thyroid cancer	0.000217	0.000863	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—TCF7L1—thyroid cancer	0.000213	0.000847	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—TSHR—thyroid cancer	0.000211	0.00084	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—PRKAR1A—thyroid cancer	0.000208	0.000826	CbGpPWpGaD
L-DOPA—SLC7A5—Hemostasis—TP53—thyroid cancer	0.000206	0.00082	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—SST—thyroid cancer	0.000205	0.000816	CbGpPWpGaD
L-DOPA—DRD1—GPCR downstream signaling—SST—thyroid cancer	0.000203	0.000809	CbGpPWpGaD
L-DOPA—DDC—Metabolism—RXRA—thyroid cancer	0.000202	0.000804	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—PTCH1—thyroid cancer	0.000202	0.000803	CbGpPWpGaD
L-DOPA—DRD3—GPCR downstream signaling—SST—thyroid cancer	0.000201	0.000798	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—MINPP1—thyroid cancer	0.0002	0.000794	CbGpPWpGaD
L-DOPA—SLC7A8—Hemostasis—AKT1—thyroid cancer	0.000199	0.000793	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—PTCH1—thyroid cancer	0.000199	0.000793	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—MEN1—thyroid cancer	0.000199	0.00079	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—CALCA—thyroid cancer	0.000198	0.000786	CbGpPWpGaD
L-DOPA—DRD2—GPCR downstream signaling—TSHR—thyroid cancer	0.000198	0.000785	CbGpPWpGaD
L-DOPA—PSIP1—Disease—KRAS—thyroid cancer	0.000197	0.000784	CbGpPWpGaD
L-DOPA—SLC7A5—Hemostasis—HRAS—thyroid cancer	0.000197	0.000784	CbGpPWpGaD
L-DOPA—DRD1—GPCR downstream signaling—CALCA—thyroid cancer	0.000196	0.000779	CbGpPWpGaD
L-DOPA—DRD3—GPCR downstream signaling—CALCA—thyroid cancer	0.000193	0.000768	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—TCF7L1—thyroid cancer	0.000192	0.000762	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—TCF7L1—thyroid cancer	0.000189	0.000752	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—SST—thyroid cancer	0.000185	0.000735	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—SST—thyroid cancer	0.000182	0.000725	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—PTCH1—thyroid cancer	0.00018	0.000714	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—TSHR—thyroid cancer	0.000179	0.000713	CbGpPWpGaD
L-DOPA—DRD4—Circadian rythm related genes—TP53—thyroid cancer	0.000179	0.000712	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—CDK1—thyroid cancer	0.000179	0.000711	CbGpPWpGaD
L-DOPA—DRD2—Circadian rythm related genes—PTEN—thyroid cancer	0.000178	0.000709	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—CALCA—thyroid cancer	0.000178	0.000707	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—PRKAR1A—thyroid cancer	0.000176	0.000702	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—CALCA—thyroid cancer	0.000175	0.000698	CbGpPWpGaD
L-DOPA—SLC7A5—Hemostasis—AKT1—thyroid cancer	0.000174	0.000692	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—NDUFA13—thyroid cancer	0.00017	0.000675	CbGpPWpGaD
L-DOPA—PSIP1—Disease—HRAS—thyroid cancer	0.000168	0.000667	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—SST—thyroid cancer	0.000164	0.000653	CbGpPWpGaD
L-DOPA—DRD1—Circadian rythm related genes—TP53—thyroid cancer	0.000161	0.000641	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—CDK1—thyroid cancer	0.000161	0.00064	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—CHST14—thyroid cancer	0.00016	0.000635	CbGpPWpGaD
L-DOPA—DRD3—Circadian rythm related genes—TP53—thyroid cancer	0.000159	0.000632	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—CDK1—thyroid cancer	0.000159	0.000632	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—CALCA—thyroid cancer	0.000158	0.000629	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—TSHR—thyroid cancer	0.000156	0.00062	CbGpPWpGaD
L-DOPA—DRD2—GPCR downstream signaling—SST—thyroid cancer	0.000154	0.000611	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—PRKAR1A—thyroid cancer	0.000153	0.00061	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—PTCH1—thyroid cancer	0.000153	0.000606	CbGpPWpGaD
L-DOPA—PSIP1—Disease—AKT1—thyroid cancer	0.000148	0.000589	CbGpPWpGaD
L-DOPA—DRD2—GPCR downstream signaling—CALCA—thyroid cancer	0.000148	0.000588	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—MEN1—thyroid cancer	0.000147	0.000583	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—TCF7L1—thyroid cancer	0.000145	0.000576	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—CDK1—thyroid cancer	0.000143	0.000569	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—TSHR—thyroid cancer	0.00014	0.000558	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—SST—thyroid cancer	0.000139	0.000555	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—TSHR—thyroid cancer	0.000138	0.000551	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—PRKAR1A—thyroid cancer	0.000138	0.000549	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—PRKAR1A—thyroid cancer	0.000136	0.000542	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—CALCA—thyroid cancer	0.000134	0.000534	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—PTCH1—thyroid cancer	0.000133	0.000527	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—MEN1—thyroid cancer	0.000132	0.000525	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—MEN1—thyroid cancer	0.00013	0.000518	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—HPGD—thyroid cancer	0.000129	0.000512	CbGpPWpGaD
L-DOPA—DDC—Metabolism—PPARG—thyroid cancer	0.000128	0.000508	CbGpPWpGaD
L-DOPA—DRD2—Circadian rythm related genes—TP53—thyroid cancer	0.000122	0.000484	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—CDK1—thyroid cancer	0.000122	0.000483	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—SST—thyroid cancer	0.000121	0.000482	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—PTCH1—thyroid cancer	0.000119	0.000474	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—PTCH1—thyroid cancer	0.000118	0.000468	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—CALCA—thyroid cancer	0.000117	0.000464	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—NRG1—thyroid cancer	0.000115	0.000457	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—SST—thyroid cancer	0.000109	0.000434	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—SST—thyroid cancer	0.000108	0.000428	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—TSHR—thyroid cancer	0.000106	0.000421	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—CDK1—thyroid cancer	0.000106	0.00042	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—CALCA—thyroid cancer	0.000105	0.000418	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—PRKAR1A—thyroid cancer	0.000104	0.000415	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—CALCA—thyroid cancer	0.000104	0.000412	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—TERT—thyroid cancer	0.000103	0.00041	CbGpPWpGaD
L-DOPA—DDC—Metabolism—PTGS2—thyroid cancer	0.0001	0.000399	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—MEN1—thyroid cancer	9.96e-05	0.000396	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—HIF1A—thyroid cancer	9.86e-05	0.000392	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—CDK1—thyroid cancer	9.51e-05	0.000378	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—CDK1—thyroid cancer	9.38e-05	0.000373	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—PTCH1—thyroid cancer	9.01e-05	0.000358	CbGpPWpGaD
L-DOPA—DDC—Metabolism—PTEN—thyroid cancer	8.76e-05	0.000348	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—NRAS—thyroid cancer	8.69e-05	0.000346	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—NRG1—thyroid cancer	8.48e-05	0.000337	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—SST—thyroid cancer	8.24e-05	0.000328	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—BRAF—thyroid cancer	8.17e-05	0.000325	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—CALCA—thyroid cancer	7.93e-05	0.000315	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—NRG1—thyroid cancer	7.63e-05	0.000304	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—TERT—thyroid cancer	7.61e-05	0.000303	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—NRG1—thyroid cancer	7.53e-05	0.000299	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—KRAS—thyroid cancer	7.48e-05	0.000297	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—TPR—thyroid cancer	7.39e-05	0.000294	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—HIF1A—thyroid cancer	7.28e-05	0.00029	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—PRKAR1A—thyroid cancer	7.27e-05	0.000289	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—CDK1—thyroid cancer	7.18e-05	0.000285	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—TERT—thyroid cancer	6.85e-05	0.000273	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—TERT—thyroid cancer	6.76e-05	0.000269	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—HIF1A—thyroid cancer	6.55e-05	0.000261	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—HIF1A—thyroid cancer	6.47e-05	0.000257	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—NRAS—thyroid cancer	6.41e-05	0.000255	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—HRAS—thyroid cancer	6.36e-05	0.000253	CbGpPWpGaD
L-DOPA—DRD5—GPCR downstream signaling—AKT1—thyroid cancer	6.18e-05	0.000246	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—BRAF—thyroid cancer	6.03e-05	0.00024	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—CCND1—thyroid cancer	5.96e-05	0.000237	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—NRAS—thyroid cancer	5.77e-05	0.00023	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—NRG1—thyroid cancer	5.76e-05	0.000229	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—PTEN—thyroid cancer	5.75e-05	0.000229	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—NRAS—thyroid cancer	5.7e-05	0.000227	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—AKT1—thyroid cancer	5.61e-05	0.000223	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—SLC5A5—thyroid cancer	5.53e-05	0.00022	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—KRAS—thyroid cancer	5.52e-05	0.00022	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—BRAF—thyroid cancer	5.43e-05	0.000216	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—BRAF—thyroid cancer	5.36e-05	0.000213	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—TERT—thyroid cancer	5.17e-05	0.000206	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—NRAS—thyroid cancer	5.13e-05	0.000204	CbGpPWpGaD
L-DOPA—DDC—Metabolism—AKT1—thyroid cancer	5.05e-05	0.000201	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—KRAS—thyroid cancer	4.97e-05	0.000198	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—HIF1A—thyroid cancer	4.95e-05	0.000197	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—KRAS—thyroid cancer	4.9e-05	0.000195	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—HRAS—thyroid cancer	4.69e-05	0.000187	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—RXRA—thyroid cancer	4.65e-05	0.000185	CbGpPWpGaD
L-DOPA—DRD4—GPCR downstream signaling—AKT1—thyroid cancer	4.56e-05	0.000181	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—KRAS—thyroid cancer	4.42e-05	0.000176	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—CCND1—thyroid cancer	4.4e-05	0.000175	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—NRAS—thyroid cancer	4.36e-05	0.000173	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—PTEN—thyroid cancer	4.25e-05	0.000169	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—HRAS—thyroid cancer	4.22e-05	0.000168	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—HRAS—thyroid cancer	4.17e-05	0.000166	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—AKT1—thyroid cancer	4.14e-05	0.000165	CbGpPWpGaD
L-DOPA—DRD1—GPCR downstream signaling—AKT1—thyroid cancer	4.11e-05	0.000163	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—BRAF—thyroid cancer	4.1e-05	0.000163	CbGpPWpGaD
L-DOPA—DRD3—GPCR downstream signaling—AKT1—thyroid cancer	4.05e-05	0.000161	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—CCND1—thyroid cancer	3.96e-05	0.000158	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—TP53—thyroid cancer	3.93e-05	0.000156	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—CCND1—thyroid cancer	3.91e-05	0.000155	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—PTEN—thyroid cancer	3.82e-05	0.000152	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—NRAS—thyroid cancer	3.79e-05	0.000151	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—PTEN—thyroid cancer	3.77e-05	0.00015	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—HRAS—thyroid cancer	3.76e-05	0.000149	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—KRAS—thyroid cancer	3.75e-05	0.000149	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—AKT1—thyroid cancer	3.73e-05	0.000148	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—AKT1—thyroid cancer	3.68e-05	0.000146	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—NRAS—thyroid cancer	3.41e-05	0.000136	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—NRAS—thyroid cancer	3.37e-05	0.000134	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—AKT1—thyroid cancer	3.32e-05	0.000132	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—KRAS—thyroid cancer	3.26e-05	0.00013	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—HRAS—thyroid cancer	3.19e-05	0.000127	CbGpPWpGaD
L-DOPA—DRD2—GPCR downstream signaling—AKT1—thyroid cancer	3.1e-05	0.000123	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—CCND1—thyroid cancer	2.99e-05	0.000119	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—KRAS—thyroid cancer	2.94e-05	0.000117	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—PPARG—thyroid cancer	2.94e-05	0.000117	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—TP53—thyroid cancer	2.9e-05	0.000115	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—KRAS—thyroid cancer	2.9e-05	0.000115	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—PTEN—thyroid cancer	2.89e-05	0.000115	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—AKT1—thyroid cancer	2.82e-05	0.000112	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—HRAS—thyroid cancer	2.77e-05	0.00011	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—TP53—thyroid cancer	2.61e-05	0.000104	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—NRAS—thyroid cancer	2.58e-05	0.000102	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—TP53—thyroid cancer	2.57e-05	0.000102	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—HRAS—thyroid cancer	2.5e-05	9.92e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—HRAS—thyroid cancer	2.46e-05	9.79e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—AKT1—thyroid cancer	2.45e-05	9.73e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—PTGS2—thyroid cancer	2.31e-05	9.18e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—KRAS—thyroid cancer	2.22e-05	8.81e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—AKT1—thyroid cancer	2.2e-05	8.76e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—AKT1—thyroid cancer	2.17e-05	8.64e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—PTEN—thyroid cancer	2.01e-05	8.01e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—TP53—thyroid cancer	1.97e-05	7.83e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—HRAS—thyroid cancer	1.88e-05	7.49e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—AKT1—thyroid cancer	1.66e-05	6.62e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—AKT1—thyroid cancer	1.16e-05	4.61e-05	CbGpPWpGaD
